Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bulevirtide - MYR Pharma

Next Previous
X
Search
Drug Profile

Bulevirtide - MYR Pharma

Alternative Names: HEPCLUDEX; 915207G; Hepcludex; MyrB; Myrcludex-B; Myrcludex-B-MYR Pharma; Myrcludex™

Latest Information Update: 30 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM; University of Heidelberg
  • Developer Hepatera; MYR Pharma
  • Class Antihyperlipidaemics; Antivirals; Hepatoprotectants; Lipopeptides
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis D
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hepatitis D
  • Phase II Hepatitis B
  • No development reported Dyslipidaemias; Non-alcoholic steatohepatitis; Primary biliary cirrhosis

Most Recent Events

  • 17 Oct 2024 Preregistration for Hepatitis D (In children, In adolescents) in European Union (SC)
  • 17 Oct 2024 The CHMP recommends approval of bulevirtide for Hepatitis D (In children, In adolescents) in European Union (SC)
  • 08 Aug 2024 Gilead completes phase-III clinical trials in Hepatitis D in US, Germany, Georgia , Italy, Russia, and Sweden (NCT03852719)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top